Healthcare
Sanofi has signed a collaboration deal with Exscientia to leverage the latter’s artificial intelligence platform and develop up to 15 oncology and immunology therapies.
Over the past ten years, Tonix’s pipeline has evolved to also comprise assets in biodefense, immunology and cancer therapeutics.
What the appearance of yet another variant shows is the “unpredictability of the emergence of SARS-CoV-2 variants,” according to the researchers who discovered IHU.
Overall, the decision to hold the conferences virtually again this year is being met with what appears to be a bit of relief.
Evidence continues to accumulate suggesting that Omicron, although significantly more infectious than previous COVID-19 strains, causes less severe disease.
More than 103,000 people in the U.S. were hospitalized on January 3, 2022, for COVID-19—the highest daily figure of hospitalizations since last summer when the Delta variant emerged.
While women are more statistically susceptible to autoimmune diseases, the research found that men with at least a mild COVID-19 infection had far more autoantibody (AAB) reactivity.
Low-income countries still struggle to get first jabs into arms. Researchers and pharma companies continue to push for low-cost vaccines and drugs worldwide.
The latest approvals mark the first time a biologic has been approved for ERA. Cosentyx is also the only biologic approved in the United States for both ERA and PsA in pediatric patients.
The FDA has approved Novartis’ new drug for lowering bad cholesterol. Leqvio is the first and only siRNA treatment that can reduce low-density lipoprotein cholesterol.
PRESS RELEASES